Compounded tirzepatide, explained: the molecule, the law and the price

Compounded tirzepatide has the same named molecule as Zepbound, but it never went through FDA review. Compounded drugs “are not FDA approved,” and the agency “does not review compounded drugs for safety, effectiveness or quality before they are marketed” ^[2]. What you get depends on the pharmacy that made it, which is why the details below matter more than the name on the label.

It’s the Zepbound molecule, made by a pharmacy

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, which together slow digestion and turn down appetite. Eli Lilly sells it as Mounjaro for type 2 diabetes, approved in May 2022 ^[8], and as Zepbound for weight, approved in November 2023 ^[9]. Zepbound added obstructive sleep apnea in adults with obesity in December 2024 ^[10]. In August 2026, Mounjaro gained a heart-risk indication for adults with type 2 diabetes at high risk ^[11].

Compounded tirzepatide comes from one of two kinds of makers. A 503A pharmacy is state-licensed and compounds for a named patient’s prescription. A 503B outsourcing facility registers with FDA and can make larger quantities, but only from ingredients on FDA’s 503B bulks list or while a drug is in shortage ^[3]. Since 2025, almost all of it comes from 503A pharmacies.

Why does a copy exist at all? Because for more than two years, from 2022, tirzepatide injection sat on FDA’s shortage list ^[1]. Demand outran Lilly’s supply, and the law lets pharmacies fill the gap during a shortage. Online programs built their businesses on that gap. The gap closed, but many of the programs stayed.

The shortage that created the market ended in December 2024

FDA first called the tirzepatide shortage resolved on October 2, 2024. It reconsidered after a lawsuit, then issued its final decision on December 19, 2024 ^[1]. Tirzepatide injection had been in shortage since 2022, and while it was, pharmacies could make copies.

FDA gave pharmacies time to wind down: 503A pharmacies until February 18, 2025 and 503B facilities until March 19, 2025. When a court denied the challengers’ preliminary injunction on March 5, 2025, FDA said the 503A period “has ended” ^[1]. Some sellers still quote October 2024 as the end date. The December decision is the one that counted.

What “patient-specific” compounding allows now

A 503A pharmacy may still compound tirzepatide for one patient’s prescription. It may not copy Zepbound or Mounjaro “regularly or in inordinate amounts.” FDA says it won’t act if a compounder “fills four or fewer prescriptions of that compounded drug product during a calendar month” ^[1].

Beyond that limit, a copy needs a reason. The prescriber must determine and document that the product “contains a change that produces a significant difference from the commercially available drug product for an identified individual patient” ^[1]. A program calling its vial “personalized” doesn’t meet that test by itself. Whether the product stays available, and for how long, is covered in is compounded tirzepatide still available.

Where the tirzepatide itself comes from

Eli Lilly doesn’t sell tirzepatide to compounders. A pharmacy buys the raw active ingredient from a chemical supplier, often overseas, and the quality of the final vial starts there.

FDA runs a “green list” import alert (66-80) meant to stop GLP-1 ingredients with “potential quality concerns” at the border ^[2]. Suppliers that FDA’s inspections show meet its manufacturing standards are exempt. You can’t tell from the vial which supplier a pharmacy used, so ask your program whether its pharmacy tests what it receives.

What compounded tirzepatide is mixed with, and why it matters

Many compounded tirzepatide products add vitamin B12, B6 or glycine. Adding a vitamin doesn’t automatically make it a different drug. FDA’s own example says a GLP-1 and B12 injection may still be “essentially a copy” when the route matches and both strengths are “within 10%” of the approved products ^[1].

Add-ins are everywhere. A 2025 secret-shopper study of 75 clinics and med spas in two states found 56.0% offered GLP-1 drugs combined with B vitamins, and 4 of 21 supplier facilities it could check were not licensed for sterile compounding ^[19].

There’s a chemistry question too. A 2026 lab study found a new impurity in compounded tirzepatide and B12 products, formed when tirzepatide reacts with certain forms of B12 ^[18]. All of its authors work for Eli Lilly, which sells Zepbound, and the authors themselves say the “clinical effects of this impurity are unknown.” It’s worth asking your program whether your product contains B12, and in what form.

How much B12 or B6 is in a given vial? That varies by pharmacy, and only the pharmacy label can tell you.

Does it work? The evidence belongs to Zepbound

No trial has tested a compounded tirzepatide product. The results people cite come from Lilly’s trials of Zepbound and Mounjaro. In SURMOUNT-1, 2,539 adults without diabetes lost 15.0%, 19.5% and 20.9% of body weight at 5, 10 and 15 mg weekly over 72 weeks, against 3.1% on placebo ^[13].

The SURMOUNT-4 line is the long-run one. People who switched to placebo after 36 weeks regained 14.0% of their weight over the next year, while those who stayed on lost another 5.5% ^[14]. Tirzepatide works while you take it. Plan cost and supply for years, not months. How compounded and brand compare side by side is in compounded tirzepatide vs Zepbound.

Safety: the label warnings plus FDA’s compounding concerns

Compounded tirzepatide carries every risk on the brand label, plus risks that come from the compounding itself. FDA had received more than 730 adverse-event reports tied to compounded tirzepatide by May 31, 2026, and says the true number is likely higher ^[2].

Zepbound’s label carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rodents, and it isn’t known whether it does in people. It isn’t for anyone with a personal or family history of medullary thyroid cancer or MEN 2 ^[6]. The label also warns about severe stomach reactions, kidney injury from dehydration, gallbladder disease, pancreatitis and allergic reactions.

Side effects are mostly digestive. In the label’s pooled weight trials, nausea hit 25% to 29% of people on Zepbound against 8% on placebo, and diarrhea 19% to 23% against 8% ^[6]. In SURMOUNT-1, 4.3% to 7.1% stopped because of side effects, against 2.6% on placebo ^[13].

• Dosing errors. FDA has received reports of adverse events tied to compounded semaglutide or tirzepatide prescribed “in doses beyond what is in the FDA-approved drug label,” and to measuring errors with compounded semaglutide vials ^[2].
• Old vials. FDA recommends using a multi-dose vial within 28 days of first use, “even if instructions from the compounder say the medication can be used for longer” ^[2].
• Warm deliveries. Don’t use any injectable GLP-1 that “arrives warm or with insufficient refrigeration” ^[2].
• Fake labels. FDA has seen products naming pharmacies that don’t exist or didn’t make them ^[2].

Storage after delivery is covered in how long compounded tirzepatide can stay out of the fridge. A full safety review is in is compounded tirzepatide safe.

Can you trust compounded tirzepatide? Check the program, not the promise

Trust comes down to the pharmacy and the prescriber, because FDA doesn’t check the product. FDA’s own list of warning signs is a good filter. Be wary of any company that ^[2]:

• claims its compounded drug is the same as an FDA-approved drug
• offers deep discounts or prices that seem too good to be true
• ships medicine that looks different from what you received before, or arrives damaged or without instructions
• doesn’t require a screening and prescription by a licensed doctor
• has no licensed doctor available after your medicine arrives
• prints spelling errors or a wrong pharmacy address on the label
• uses a pharmacy name on the label that you think might be fake

One more line to hold: retatrutide, a newer Lilly drug still in trials, is not compounded tirzepatide. FDA says “retatrutide and cagrilintide cannot be used in compounding under federal law” ^[2]. Any seller offering it is outside the law, whatever the label says.

How it’s supplied: vials, not pens

Brand tirzepatide comes as Lilly single-dose pens, single-dose vials, multi-dose vials and KwikPens, each holding a fixed labeled dose ^[6]. Compounded tirzepatide usually arrives as a pharmacy-labeled multi-dose vial. FDA’s advice is to discard any such vial 28 days after first use ^[2].

That also answers “how do I know if my tirzepatide is compounded?” A Lilly pen, vial or KwikPen with the Zepbound or Mounjaro name is the approved drug. A vial or bottle labeled by a compounding pharmacy, often with “B12” or “glycine” in the name, is compounded. A label with no pharmacy name, misspellings or an address you can’t find is one of FDA’s red flags ^[2]. Dose questions belong with your prescriber; the label-level facts are in compounded tirzepatide starting dose.

Oral and sublingual compounded tirzepatide have no trial behind them

No oral form of tirzepatide is FDA-approved. A PubMed search for this update found no published trial of an oral or sublingual tirzepatide product. Several programs sell compounded tirzepatide tablets or drops anyway.

Getting a peptide drug through the gut is hard. The one approved GLP-1 peptide pill, semaglutide, needs an absorption enhancer and a fasting routine, and still absorbs only about 1% to 2% of its dose ^[7]. Nobody has shown how much tirzepatide a compounded drop or tablet delivers. If you’re offered one, ask what evidence the program has that it works.

What compounded tirzepatide costs right now

Compounded tirzepatide injections run $85–$433 a month across 69 online programs as of this update. The table shows each program’s monthly price on the plan most people start with, and how it bills.

Also offered by (no standing monthly price published): Bodybuilding HealthPartner, Midi Health.

The brand has come down a long way. Through LillyDirect, Zepbound vials and KwikPens list at $299 a month for the 2.5 mg starting dose and $399 for 5 mg, and $449 a month for 7.5 to 15 mg when you refill within 45 days as of this update ^[12]. Lilly’s regular price is $499 for 7.5 mg and $699 for 10 to 15 mg. Lilly also notes that 2.5 mg “is a starting dose and is not approved as a maintenance dose.”

So check the price at the dose you’ll stay on, not the dose you start on. Programs such as Midi Health charge more as the dose rises. A four-week billing cycle means 13 charges a year. The full cost breakdown is in how much compounded tirzepatide costs, and programs side by side are on the compounded tirzepatide providers scorecard.

Getting a prescription

You need a licensed prescriber, usually through a telehealth program that runs an intake visit and sends the prescription to a pharmacy. Some programs name that pharmacy on their own site: Embody does, for example, while BrightMeds does not. Before you pay, ask which pharmacy fills your order and whether it’s licensed in your state. Then check it yourself with your state board of pharmacy.

The full route, including the brand option through LillyDirect, is in where to get compounded tirzepatide. If you’re thinking about a smaller dose than the label uses, read microdosing tirzepatide first; no trial has tested it. The semaglutide side of the story is in compounded semaglutide.

Questions to ask before your first order

1. Which pharmacy compounds my tirzepatide, and is it licensed where I live?
2. What else is in the vial: B12, B6, glycine? In what amount and form?
3. What documented reason makes a compounded product right for me instead of Zepbound?
4. Does the price change when my dose goes up?
5. Who do I contact if a shipment arrives warm or the label looks wrong?
6. If compounded supply stops, how would you move me to the brand?